Tetra Bio-Pharma Announces PPP002 Program Update Following Type B Meeting with U.S. FDA
Shorter regulatory pathway confirmed by FDA and potential for Schedule 3 classification ORLEANS, Ontario, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: …